Search
Muparfostat
go.drugbank.com/drugs/DB05808InvestigationalMuparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic
Doxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigational[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Vortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalSome serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional … SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePericiazine
go.drugbank.com/drugs/DB01608ApprovedPericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade. … It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected.
Atovaquone
go.drugbank.com/drugs/DB01117ApprovedInvestigationalAtovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Antithrombin Alfa
go.drugbank.com/drugs/DB11166ApprovedAntithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[L27996] In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in … [L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis.
Betula pendula tar oil
go.drugbank.com/drugs/DB11361ApprovedNutraceutical[L1113] By the FDA, it is considered under the substances approved to be added to the food. … This oil is usually obtained by using both hydrodistillation and micro-distillation[A33154] and it is conformed mainly by [DB11143] and [DB11359].
Necitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnIt functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression … Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigational[L40793] While some patients may remain asymptomatic, typical symptoms of MF arise from abnormalities in blood cell production and may therefore include various cytopenias, infections, splenomegaly, and … [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia.